Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Cure in metastatic disease

Cure in metastatic disease editorial memo (2018) 11:163–164 https://doi.org/10.1007/s12254-018-0423-z Hannes Kaufmann Received: 10 July 2018 / Accepted: 10 July 2018 / Published online: 17 July 2018 © Springer-Verlag GmbH Austria, part of Springer Nature 2018 One of the principles in oncology over decades was is a relatively new concept and was originally de- that patients diagnosed with metastatic cancer were fined as five or fewer metastatic sites. It was pro- unlikely to be cured of their disease by any means. At posed as a clinically significant state separate from best, treatment with classical chemotherapy ended in the polymetastatic disease [3] and considered to be extended progression-free or overall survival. Com- less aggressive than other metastatic phenotypes [4]. plete remissions from systemic standard chemother- Metastasectomy should be confined to those pa- apy are uncommon, and only a fraction of complete tients groups for whom benefit has been proven, in responders remain progression free for a prolonged particular of discussions according to clinical and period in most malignant diseases. experimental evidence supporting the role of surgery Exceptions of this paradigm according to more and inflammation as potential triggers for disease effective systemic and local treatment strategies are recurrence [5]. Hodgkin disease, some non-Hodgkin lymphomas, Recently http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Loading next page...
 
/lp/springer-journals/cure-in-metastatic-disease-ONtvRWHIn8

References (7)

Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer-Verlag GmbH Austria, part of Springer Nature
Subject
Medicine & Public Health; Oncology; Medicine/Public Health, general
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-018-0423-z
Publisher site
See Article on Publisher Site

Abstract

editorial memo (2018) 11:163–164 https://doi.org/10.1007/s12254-018-0423-z Hannes Kaufmann Received: 10 July 2018 / Accepted: 10 July 2018 / Published online: 17 July 2018 © Springer-Verlag GmbH Austria, part of Springer Nature 2018 One of the principles in oncology over decades was is a relatively new concept and was originally de- that patients diagnosed with metastatic cancer were fined as five or fewer metastatic sites. It was pro- unlikely to be cured of their disease by any means. At posed as a clinically significant state separate from best, treatment with classical chemotherapy ended in the polymetastatic disease [3] and considered to be extended progression-free or overall survival. Com- less aggressive than other metastatic phenotypes [4]. plete remissions from systemic standard chemother- Metastasectomy should be confined to those pa- apy are uncommon, and only a fraction of complete tients groups for whom benefit has been proven, in responders remain progression free for a prolonged particular of discussions according to clinical and period in most malignant diseases. experimental evidence supporting the role of surgery Exceptions of this paradigm according to more and inflammation as potential triggers for disease effective systemic and local treatment strategies are recurrence [5]. Hodgkin disease, some non-Hodgkin lymphomas, Recently

Journal

memo - Magazine of European Medical OncologySpringer Journals

Published: Jul 17, 2018

There are no references for this article.